Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECtS: Paracetamol in Severe Malaria
NCT04251351Phase 3Unknown
- Sponsor
- University of British Columbia
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetaminophen in acute kidney injury (AKI) (2 arms), sponsored by University of British Columbia. Primary endpoints: Acute kidney injury (AKI) or death among patients enrolled without AKI at 7 days and Acute kidney injury (AKI) progression or death among patients enrolled with AKI at 7 days. Status: unknown.
02
Drugs
acetaminophen
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04251351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251351.